Drug-Induced Sexual Dysfunction
SSRIs/SNRIs, 5-ARIs (finasteride/PFS), antipsychotics, antihypertensives, spironolactone, chemotherapy
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not an FDA product (adverse-effect survey across multiple approved drug classes)
Reference only. Not medical advice.
What can go wrong
The risk is misattribution in both directions: diagnosing 'low T' and starting hormone therapy when the cause is a reversible medication effect, or abruptly stopping a needed psychiatric or cardiac drug to chase a sexual side effect. On post-finasteride syndrome specifically, the risk is overclaiming in either direction - asserting it is proven (unsupported) or dismissing distressed patients as having a myth (also unsupported); the evidence cannot yet confirm or refute it.
This is something to take to a clinician. The Atlas can tell you what is known about drug-induced sexual dysfunction in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
A large share of male sexual dysfunction is iatrogenic - caused by prescribed drugs rather than by hormone deficiency. The major offenders span psychiatry (SSRIs/SNRIs, antipsychotics), urology/dermatology (5-alpha-reductase inhibitors), cardiology (thiazides, beta-blockers, spironolactone), and oncology (chemotherapy, anti-androgens). Each works by a distinct mechanism - serotonergic suppression of arousal, hyperprolactinemia, DHT reduction, vascular and autonomic effects, anti-androgen action, gonadotoxicity. The most contested entry is post-finasteride syndrome (PFS): a reported persistence of sexual, neurological, and psychological symptoms after stopping finasteride whose existence as a defined entity remains genuinely disputed.
Before you label it 'low T,' check the medicine cabinet. Several of the most common prescriptions in medicine cause sexual dysfunction directly.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Mechanisms by class: SSRIs/SNRIs raise synaptic serotonin, which suppresses dopaminergic/nitric-oxide pathways of arousal and delays ejaculation/orgasm. 5-alpha-reductase inhibitors block conversion of testosterone to the more potent DHT, reducing androgenic signaling in genital tissue. Antipsychotics (especially risperidone/paliperidone) block dopamine D2 receptors and raise prolactin, which suppresses GnRH and libido. Spironolactone is a direct androgen-receptor antagonist and mild anti-androgen. Thiazides and non-selective beta-blockers impair erectile function via vascular/autonomic effects. Cytotoxic chemotherapy and GnRH-agonist/anti-androgen cancer therapy directly damage the testes or block androgen signaling.
Post-finasteride syndrome - what is and isn't established
Most drug-induced sexual dysfunction is reversible on stopping the drug, and that is well established. The genuine controversy is post-finasteride syndrome (PFS) - the claim that a subset of men have persistent sexual, neurological, and psychological symptoms that do NOT resolve after discontinuation. Honest grading: the EXISTENCE of PFS as a discrete clinical entity remains disputed. Manufacturer prescribing information and trial data historically stated that sexual adverse effects resolve on discontinuation and do not increase with duration; an FDA-mandated label change in April 2011 added persistence-of-erectile-dysfunction-after-discontinuation language for finasteride, reflecting post-marketing reports. The Post-Finasteride Syndrome Foundation petitioned the FDA in 2017 to halt sales citing persistent dysfunction, depression, and suicidality; the FDA did not grant the petition. Pharmacovigilance (FAERS) disproportionality analyses detect a signal for persistent sexual adverse events, but signal detection cannot establish causation, prevalence, or mechanism, and is vulnerable to reporting bias and intense online advocacy. The fair statement: real, distressing patient reports exist; a biologically plausible neurosteroid mechanism has been proposed; but rigorous evidence cannot yet confirm or refute PFS as a defined syndrome, and prevalence is unknown. Ēnel does not assert it is real OR fake - it is unresolved.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Full medication reconciliation
- Prolactin (if antipsychotic involved)
- Testosterone where indicated to exclude concurrent hypogonadism
What people get wrong
Often saidSexual dysfunction means your testosterone is low
ActuallyA very common cause is the medicine cabinet, not the gonads. SSRIs, finasteride, certain antipsychotics, spironolactone, thiazides, and beta-blockers all cause sexual dysfunction by non-hormonal mechanisms. A medication review should precede a low-T diagnosis.
Often saidPost-finasteride syndrome is proven
ActuallyIts existence as a defined entity is genuinely disputed. There are real patient reports, an FDA label change in 2011, and pharmacovigilance signals - but signal detection is not proof of causation, prevalence is unknown, and rigorous studies can neither confirm nor refute it. Honest answer: unresolved.
Often saidPost-finasteride syndrome is definitely a myth
ActuallyEqually unsupported. Dismissing distressed patients ignores the FDA label change and post-marketing signals. The defensible position is uncertainty, not certainty in either direction.
Who profits, and who pushes back
Culley Carson
Framed PFS as a question current evidence can neither confirm nor refute as a nosological entity.
What we do not know
- Is post-finasteride syndrome a distinct entity, an enrichment of pre-existing/coincident conditions, or a reporting artifact?
- Why do some men report persistence after a drug whose effects are otherwise reversible - is there a neurosteroid mechanism?
At a glance
- SSRIs/SNRIs
- Delayed ejaculation, low libido, anorgasmia (serotonergic)
- 5-ARIs (finasteride/dutasteride)
- ED, low libido; disputed persistent PFS
- Antipsychotics
- Hyperprolactinemia (esp. risperidone, paliperidone) -> low libido/ED
- Cardiac drugs
- Thiazides, non-selective beta-blockers, spironolactone implicated
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Drug-Induced Sexual Dysfunction. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA finasteride label change2011
Added language on persistence of erectile dysfunction after discontinuation, reflecting post-marketing reports
PFS Foundation FDA citizen petition2017
Requested halting finasteride sales over persistent sexual/psychological effects; FDA did not accede
FAERS disproportionality analyses of 5-ARIs2018-2025
Detected reporting signals for persistent sexual dysfunction; authors caution signal detection cannot prove causation
Carson review 'Post-finasteride syndrome: real or myth?'2024
Concluded existence as a nosological entity can be neither confirmed nor refuted on current evidence